T he GNAS gene encodes the Gα s stimulatory subunit of heterotrimeric G proteins, which mediate G-protein-coupled receptor (GPCR) signalling, a central mechanism by which cells sense and respond to extracellular stimuli 1 . Ligand stimulation of GPCRs promotes GDP for GTP exchange on Gα s , enabling Gα s to engage effectors. The primary target is adenylyl cyclase, which generates the second messenger cAMP, an activator of protein kinase A (PKA), cyclic nucleotide-gated ion channels and EPAC1/2 guanine-nucleotide exchange factors-although GNAS also has reported cAMPindependent functions 2,3 . In many tissues, GNAS-cAMP signalling maintains quiescence or cellular differentiation 4-8 . However, multiple human cancer types exhibit recurrent gain-of-function mutations in the pathway, most frequently targeting GNAS 1 . These context-specific oncogenic functions are not well understood. Additionally, activating GNAS mutations often co-exist with driver mutations in KRAS 9-13 (ref. 13 accessed from www.cbioportal.org), thus it is uncertain whether mutant GNAS remains important for the growth of tumours once they are established 14 . GNAS mutations and amplifications are particularly common in pancreatic tumorigenesis where their presence distinguishes two major precursors of invasive PDA; pancreatic intraepithelial neoplasias (PanINs) and IPMNs both exhibit frequent KRAS mutations, whereas GNAS mutations are exclusive to IPMN (present in ~41-75% of IPMNs 9,10,15 and ~2-11% of total PDAs 11, 12, 15, 16 ).
Gnas R201C is critical for pancreatic tumour maintenance. The circuits supporting the growth of established IPMNs and resulting PDA have yet to be defined. Our Dox-inducible system enabled us to investigate whether Gnas R201C is required for tumour maintenance. To this end, KGC animals were provided with Dox until palpable tumours were present, and then Dox was withdrawn ( Fig. 3a , Dox-Off group). These mice showed immediate improvements in body condition, including reductions in abdominal size and cyst fluid ( Fig. 3b and Supplementary Fig. 2a ). Remarkably, they remained healthy for > 20 weeks, whereas the Dox-On group required euthanasia within 1-3 weeks of tumour detection (Fig. 3c ). Serial analyses of tumours following Dox withdrawal revealed rapid loss of dysplastic papillary features, reduced mucins and decreased proliferation ( Fig. 3d ), without evidence of apoptosis ( Supplementary Fig. 2b ). Furthermore, organoids derived from KGC IPMNs and KGPC ER PDAs remained dependent on Gnas R201C for tumour formation and maintenance, as assessed by injection into SCID mice ± Dox supplementation and by acute Dox withdrawal following tumour establishment, respectively ( Fig. 3e-g) . Thus, Gnas R201C is critical for sustained pancreatic tumour growth, despite the presence of concurrent Kras and Tp53 mutations. This tumour maintenance function and induction of PDA from IPMNs rather than PanINs suggest that mutant Gnas may establish a unique molecular program in PDA distinct from that resulting from Kras/Tp53 mutations alone.
Gnas R201C supports pancreatic tumour growth via cAMP-PKA signalling. We used tumour-derived organoids from the KGC (IPMN) and KGC shp53 (PDA) models to define the oncogenic mechanisms of Gnas R201C . Dox withdrawal abrogated organoid growth in vitro, indicating that Gnas R201C -driven tumour maintenance involves cellintrinsic mechanisms. Gnas R201C extinction led to a decrease in cAMP whereas treatment with the adenylyl cyclase agonist forskolin (FSK) boosted cAMP levels and rescued organoid growth ( Fig. 4a-d and Supplementary Fig. 3a-c) . These data are consistent with a primary role for adenylyl cyclase/cAMP signalling downstream of Gnas R201C , rather than engagement of non-canonical targets 3, 19 . cAMP activates multiple effectors (Fig. 4c) including PKA, whose subunits are abundantly expressed in KGC cultures, and EPAC1/2, which are virtually undetectable ( Supplementary Fig. 3d ). Accordingly, activation of PKA with the cAMP analogue Sp-8-Br-cAMPS (8-bromoadenosine-3′ ,5′ -cyclic monophosphorothioate, Sp-isomer, acetoxymethyl ester) rescued colony formation, whereas the EPAC-specific agonist 8-pCPT-2′ -O-Me-cAMP (8-(4-chlorophenylthio)-2′ -O-methyladenosine-3′ , 5′ -cyclic monophosphate) had no effect ( Fig. 4d ; PKA activation by FSK and Sp-8-Br-cAMPs is shown in Supplementary Fig. 3e ). Moreover, Gnas R201C extinction decreased PKA signalling in vitro and in vivo as reflected by phosphorylation of VASP and proteins detected with phospho-PKA substrate antibody (Fig. 4e,f and Supplementary  Fig. 3g ; Dox-dependent regulation of Gnas expression in vivo is shown in Supplementary Fig. 3f,g) . Correspondingly, ectopic expression of a dominant-negative PKA mutant (PKA DN ) attenuated growth of KGC and KGC shp53 organoids in vitro, and suppressed tumorigenesis following organoid injection in vivo ( Fig. 4g-i and Supplementary  Fig. 3h ,i; inhibition of PKA signalling by PKA DN is shown in Fig. 5c ). These experiments establish PKA as a principal effector of oncogenic Gnas R201C .
The salt-inducible kinases are critical targets of oncogenic Gnas-PKA signalling in pancreatic tumours. Creb, the classic PKA substrate, and several other direct or indirect PKA targets implicated in growth control either showed no phosphorylation changes (Creb, Yap and β -catenin) or increased activating phosphorylation (ERK1/2) following Gnas R201C silencing ( Supplementary Fig. 4a ) [20] [21] [22] . A broader network by which PKA integrates responses to hormonal cues involves phosphorylation of salt-inducible kinases (Sik1, Sik2 and Sik3), which prevents SIKs from phosphorylating key substrates 21 (Fig. 5a ). Similarly to cAMP/PKA signalling, SIKs have context-dependent tumour-promoting and -suppressing roles [23] [24] [25] . Consistent with Gnas R201C -mediated control of this pathway in KGC cells, Dox withdrawal reduced Sik2 phosphorylation at each documented PKA site ( Fig. 5b) 26, 27 . Accordingly, there was increased phosphorylation of established SIK targets, CrtcRTC2-S171, Crtc2-S275 and Hdac7-S155 ( Fig. 5b) 21, 26 . PKA DN expression recapitulated these effects ( Fig. 5c ). Thus, oncogenic Gnas R201C -PKA signalling leads to sustained inhibition of SIKs in pancreatic tumour cells.
Sik1, Sik2 and Sik3 have overlapping functions and each is readily detectable in Gnas-mutant organoids (Sik2 and Sik3 are visualized by immunoblot with available antibodies whereas Sik1 is not, but has the highest mRNA levels; Fig. 5f and Supplementary Fig. 4b ). This prompted us to study their role as a group using small-molecule pan-SIK inhibitors (HG-9-91-01 and KIN-112) 26, 28 . Remarkably, these compounds rescued proliferation of KGC organoids following Gnas R201C silencing, with effects proportional to the extent of SIK inhibition gauged by Crtc2 phosphorylation (Fig. 5d,e ). Conversely, expression of the SIK2-S4A mutant 26, 27 , which is resistant to cAMP/ PKA-dependent phosphorylation, strongly suppressed growth of KGC organoids compared to WT SIK2 ( Supplementary Fig. 4c ). We corroborated these studies with CRISPR-mediated gene editing using two independent sets of sgRNAs to knock out Sik1-3 in KGC cells. qRT-PCR and immunoblot confirmed that Sik1-3 KO cells lost Sik1-3 expression and lacked induction of Crtc2 phosphorylation following
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Dox withdrawal ( Supplementary Figs. 4d and 5f ). Importantly, Sik1-3 KO rescued both organoid growth in vitro and subcutaneous tumour growth following Gnas R201C silencing (Fig. 5g,h) . Thus, the cAMP-PKA-SIK axis is critical for Gnas R201C -driven tumour growth.
To test this circuit in human PDA, we generated a cell line (950-5-BLK) from a human PDA harbouring KRAS G12V , GNAS R201H and TP53 R273C mutations (Fig. 6a) , and compared this model with a series of KRAS-mutant/GNAS WT patient-derived and established PDA cell lines. Immunoblot analysis revealed that 950-5-BLK cells had high relative levels of phospho-PKA substrates and phospho-VASP and low phospho:total CRTC2 levels, consistent with constitutive PKA activity and impaired SIK function (Fig. 6b ). 
Articles
Nature Cell Biology
Moreover, shRNA-mediated knockdown of GNAS promoted SIK activity specifically in 950-5-BLK cells, as reflected by increased CRTC2 phosphorylation ( Fig. 6c ). Ectopic expression of PKA DN also increased CRTC phosphorylation in 950-5-BLK cells ( Fig. 6e ). Importantly, PKA DN inhibited the growth of 950-5-BLK tumour spheres and subcutaneous xenografts, while having minimal effects in three human GNAS-WT PDA models ( Fig. 6d-f ). Moreover, SIK inhibitors rescued growth of PKA DN expressing organoids ( Fig. 6g ). Therefore, oncogenic GNAS-PKA-SIK signalling is a conserved mechanism of murine and human pancreatic tumour maintenance.
Mutant GNAS reprograms lipid metabolism in pancreatic tumour cells. The GNAS-PKA-SIK pathway modulates lipolysis and lipid synthesis in liver and adipose tissue [29] [30] [31] [32] . Notably, global Articles Nature Cell Biology quantitative proteomics of KGC tumour organoids ± Dox and gene set enrichment analysis (GSEA) revealed enrichment of processes relating to lipid metabolism and in components of the peroxisome (microbody), an organelle required for processing of very long-chain fatty acids and generation of ether lipids 33,34 ( Fig. 7a and Supplementary Fig. 5a ). qRT-PCR following Dox removal or treatment with the PKA inhibitor KT5720 indicates that Gnas R201C -PKA signalling supports the transcription of multiple lipid metabolism enzymes ( Supplementary Fig. 5b ). Comparable expression changes were observed following acute Gnas R201C silencing in subcutaneous KGC tumours in vivo ( Supplementary Fig. 5c ). Moreover, PKA DN caused similar expression changes in human GNAS-mutant 950-5-BLK cells, while not significantly affecting GNAS-WT PDA models ( Supplementary Fig. 5d ). Based on these observations and the central role of GNAS-PKA-SIK signalling in regulating lipid metabolism in normal tissues 21, [29] [30] [31] 35 , we examined the potential functions of oncogenic Gnas R201C in reprogramming tumour cell metabolism. Free fatty acids synthesized de novo or imported into the cell are rapidly esterified to glycerolipids/triglycerides (TG) 29, [36] [37] [38] . Thus, complementary lipolytic processes are required to provide fatty acid substrates for signalling, structural, and metabolic purposes, and recent studies have shown that various oncogenes coordinate this lipid network in different tumour types 29, [38] [39] [40] . Using BODIPY staining and lipidomic profiling of KGC organoids, we found that Gnas R201C inactivation caused a decrease in total lipids including TG, as well as specific depletion of several lipid classes ( Supplementary Fig. 6a-c ). There was a particularly pronounced reduction in ether lipids, in keeping with the downregulation of the ether lipid biosynthesis enzymes Far1 and Agps (Supplementary Figs. 5b,c and 6d,e). However, the ratio of monoglycerides/triglycerides (MG:TG) and monoglycerides/diglycerides (MG:DG) was decreased following Table 2 . Original scans of the immunoblots are shown in Supplementary Fig. 8 . Significance was analysed using two-tailed Student's t-test. P < 0.05 was considered statistically significant. Source data are provided in Supplementary  Table 2 . Original scans of the immunoblots are shown in Supplementary Fig. 8 .
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Dox withdrawal ( Fig. 7b ), suggesting that Gnas R201C promotes lipid hydrolysis in addition to lipid synthesis and remodelling.
In Kras-mutant pancreatic cancers lacking Gnas mutations, both lipid accumulation and fatty acid oxidation (FAO) are restricted by Kras signalling 41 . By contrast, our data indicate that these processes are activated by Gnas R201C (despite concurrent Kras G12D mutations), prompting us to examine lipid metabolism in further detail. In adipocytes, the Gnas-PKA-SIK axis controls lipolysis through PKA-mediated phosphorylation events as well as SIKdependent transcriptional changes 21, [29] [30] [31] 38 . Accordingly, Gnas R201C extinction in KGC organoids led to loss of activating phosphorylation (Ser660) of hormone-sensitive lipase (HSL) (Fig. 7c ) and reduced expression of other lipases ( Supplementary Fig.  5b-d and Supplementary Fig. 6f ). Reduced phospho-HSL was also observed following Dox withdrawal in established tumours in vivo ( Supplementary Fig. 6h ). Fatty acids taken up by the cell, synthesized, or derived from lipolysis can be broken down through FAO, a process in which PKA has also been implicated [42] [43] [44] .
Correspondingly, assessment of CO 2 release from 14 C-labelled oleate in KGC cultures ± Dox demonstrated that Gnas R201C was required to sustain FAO activity (Fig. 7d ). The use of PKA DN confirmed that this effect was PKA-dependent ( Fig. 7e ). PKA DN also suppressed FAO in human GNAS-mutant (950-5-BLK) but not GNAS-WT PDA cells ( Supplementary Fig. 6g ). Importantly, FSK or SIK inhibitor treatment or SIK1-3 KO rescued FAO following Gnas R201C extinction ( Supplementary Fig. 6i,j) . Thus, Gnas R201C activates multiple aspects of lipid metabolism including potentiating FAO through the PKA-SIK axis.
LC-MS/MS-based profiling of 95 polar metabolites spanning central metabolic pathways revealed that Gnas R201C silencing in KGC cells led to a decrease in acetyl-CoA (Fig. 7f ), which is a main product of FAO. Moreover, shRNA-mediated silencing of carnitine palmitoyltransferase 1a (Cpt1a), the rate-limiting enzyme for fatty acid transport into mitochondria, reduced acetyl-CoA levels in KGC organoids but not in Gnas WT PDA organoids from a Kras-mutant/Tp53-deficient genetically engineered mouse model ) . h, Relative growth of Gnas mutant and WT organoids ± FSK (10 μ M). i, Relative FAO rates. j,k, Impact of Cpt1a knockdown using two different shRNAs on organoid growth (j) and tumorigenesis (k) following subcutaneous injection. b,d,e,h, N = 3; f, N = 5; j, N = 4 independent biological replicates; c,g, immunoblots were performed two times with similar results; i, N = 4 cell lines for Gnas MUT and N = 3 cell lines for Gnas WT ; k, N = 6 tumours per group. Error bars (b,d-f,h-k) are ± s.e.m). Significance was analysed using two-tailed Student's t-test. P < 0.05 was considered statistically significant. Source data are provided in Supplementary Table 2 . Original scans of the immunoblots are shown in Supplementary Fig. 8 .
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( Supplementary Fig. 6k ). These data suggest that FAO supports acetyl-CoA levels in these tumour cells.
Metabolic reprogramming is a hallmark of PDA driven by oncogenic Kras and involves enhanced glycolysis and attenuated FAO 41, 45 . Our studies indicated that Gnas R201C induces a distinct set of metabolic processes, suggesting that there may be differences in the circuitry of Kras-mutant pancreatic tumours depending on Gnas mutational status. Notably, comparison of four independently-derived lines per group of murine Gnas-mutant and Gnas WT PDA organoids revealed opposite patterns of PKA and SIK activity ( Fig. 7g) , consistent with observations in human PDA cells (Fig. 6b) . Moreover, FSK treatment compromised the growth of multiple Gnas WT PDA organoids while promoting that of Gnasmutant organoids (Fig. 7h) . Conversely, Gnas-mutant organoids were highly sensitive to PKA DN expression ( Fig. 4h, top) or treatment with the PKA inhibitor, KT5720, while Gnas WT PDA organoids were largely unaffected ( Supplementary Fig. 7a,b) . Thus, the biological effects and activation state of the cAMP-PKA-SIK pathway distinguishes these subsets of Kras-mutant pancreatic tumours.
Notably, Gnas R201C -expressing cells had a greater FAO rate relative to Gnas WT cells ( Fig. 7i and Supplementary Fig. 7c ). Furthermore, Gnas-mutant organoids were specifically responsive to inhibition of lipid degradation, using the lipase/carboxyesterase inhibitor WWL113 46 (Supplementary Fig. 7d ), and showed preferential sensitivity to FAO inhibition by Cpt1a knockdown or treatment with the FAO inhibitor 4-bromocrotonic acid (BrCA) ( Fig. 7j and Supplementary Fig. 7e,f) . Cpt1a knockdown also impaired tumourigenicity in vivo (Fig. 7k) . By contrast, Gnasmutant and Gnas WT organoids responded similarly to glycolysis inhibition using 2-deoxyglucose (2DG) or oxamate, indicating that Gnas-mutant pancreatic cancer cells do not exhibit general increased vulnerability to metabolic stress and reinforcing the specificity of the observed responses to inhibition of lipid metabolism ( Supplementary Fig. 7g,h ).
Discussion
The oncogenic functions of GNAS remain under-investigated despite increasing evidence for its mutational activation in human tumours. Moreover, there is a critical need to understand the diversity of pancreatic cancer subtypes, including IPMN-associated tumours, which comprise ~10% of PDA 10, 11, 15, 16, 47 . By establishing an inducible GEM model that recapitulates the human IPMN-PDA sequence, we demonstrate that Gnas R201C cooperates with Kras G12D and Tp53 loss to drive tumour initiation and progression and has a persistent role in maintenance of advanced malignancy. This function is mediated by PKA-dependent inactivation of Sik1-3, establishing SIKs as critical tumour suppressors and suggesting the therapeutic potential of inhibition of GNAS-PKA signalling in GNAS-mutant pancreatic tumours. Comparison of Kras G12D -driven pancreatic tumour models defined opposing roles for the PKA-SIK pathway and distinct metabolic requirements depending on Gnas mutational status. Thus, Kras-mutant pancreatic tumour cells have heterogeneous circuits for growth and nutrient utilization governed by their combinations of cooperating gene mutations.
Our studies reveal negative regulation of SIKs as a primary mechanism by which Gnas R201C -PKA drives pancreatic tumorigenesis. Whereas inactivating mutations of SIKs are infrequent in human cancers, perhaps reflecting redundancy, the mutant-GNAS-PKA pathway inhibits SIK1-3, thereby unmasking their tumour suppressor activity. Genetic alterations in pathways potentially converging on SIK signalling are found across several sporadic tumour types and include other instances of GNAS mutations, mutation of PKA subunits, and loss-of-function of LKB1/STK11, an activator of SIKs 1,48-50 . Moreover, genetic syndromes involving GNAS (McCune-Albright syndrome), PKA (Carney complex) and LKB1 (Peutz-Jeghers syndrome) have overlapping features including abnormal pigmentation and predisposition to a spectrum of tumours, including IPMN 51, 52 . Thus, our findings suggest the possibility that SIK inactivation may comprise a common node contributing to these different diseases.
The GEM models provide insights into the natural history of IPMNs and their relationship to PanIN and PDA. Gnas R201C induction promotes IPMN with long latency and shows dramatic cooperation with Kras G12D , shifting Kras G12D -driven PanIN to more proliferative and dysplastic IPMN lesions (see also previous work 53 reporting a non-inducible transgenic model of GNAS-/ KRAS-mutant IPMN). Additionally, while previous studies have suggested that the distinct features of IPMN versus PanIN may reflect differing cells of origin (proposed to arise from ducts and acinar cells, respectively) 54 , our observations using the Ptf1a-Cre ER system show that acinar cells readily give rise to IPMNs (Fig. 2b) , indicating that underlying mutations (rather than cell of origin) direct this neoplastic phenotype. Moreover, in humans, IPMNs often remain benign, and GNAS mutations are associated with relatively indolent tumours across several tissues; therefore, there is uncertainty regarding the relationship between IPMNs and PDA and the potential of mutant-GNAS to drive invasive tumour growth 14 . Consistent with having constrained malignant potential, GNAS/KRAS-mutant murine IPMNs did not typically progress to PDA. However, Tp53 deficiency in the KGPC ER model and acute Tp53 inactivation in KGC organoids resulted in invasive PDA, revealing Tp53 as a central barrier for IPMN advancement and reinforcing the paradigm of direct IPMN-to-PDA progression (Fig. 2) 10 .
Established murine KGC and KGPC tumours remained dependent on mutant-Gnas/PKA signalling for sustained growth. Our data in 950-5-BLK cultures and xenografts indicate that at least a subset of GNAS-mutant human PDA is likely to remain dependent on this pathway. The KGC tumours exhibit rapid and progressive responses to Gnas R201C inactivation ( Fig. 3e-g) . Within days of Dox withdrawal, cell proliferation, mucin expression and dysplastic histologic features were reduced, followed by a gradual loss of papillary architecture (Fig. 3d ). Unlike Kras G12D extinction in the KPC model of PDA 45, 55 , there was no evidence of apoptosis ( Supplementary  Fig. 2 ). These observations highlight distinct modes of oncogene addiction whereby different activated oncogenes support the neoplastic state by variously controlling proliferation, survival, differentiation and/or tumour-stroma interactions.
Our data also link oncogenic Gnas signalling to regulation of lipid metabolism. Mutant-Gnas promoted both maintenance of triglyceride levels and supported lipid breakdown via FAO. Coordinated triglyceride synthesis and degradation have been observed in other tumour types 40, [56] [57] [58] , including subsets of lung cancers where mutant-KRAS induces lipid uptake, triglyceride production, and FAO 39 . We also present evidence that mutant-Gnas contributes to steady-state levels of acetyl-CoA, the substrate for fatty acid synthesis, TCA cycle activity and protein acetylation. Whereas acetyl-CoA is primarily derived from glucose or acetate in many cancers 59 , our data suggest that FAO may be an important contributor to acetyl-CoA pools in Gnas-mutant pancreatic tumours cells. Overall, our study highlights the broad rewiring of lipid metabolism by Gnas R201C , although fully deciphering the metabolic processes controlled by mutant Gnas will require metabolic labelling analysis and assessment of how intracellular and extracellular nutrient sources are mobilized.
Finally, our study illustrates the dichotomous oncogenic versus tumour suppressive functions of cAMP/PKA signalling. We show that in the context of common Kras G12D ± p53 mutations the cAMP-PKA pathway has opposite effects on pancreatic tumour cell proliferation depending on Gnas mutational status. Thus, Kras-mutant pancreatic tumours have heterogeneous circuits for growth and governed by their combinations of cooperating gene mutations.
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Since > 30% of FDA-approved drugs target GPCRs and largely function as cAMP-PKA modulators 60 , understanding the effects of cAMP on tumour growth may predict new treatment avenues repurposing these compounds.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0122-3. Lentiviral and retroviral vectors. Lentiviruses and retroviruses were produced in 293T cells by standard protocols with the packaging plasmids (pCMV-dR8.91 or pCL-Eco and pMD2.G (VSVG). To generate the pLX303-Dominant negative PKA-HA (PKA DN ) vector, m7 pDN-PKA-GFP (Addgene plasmid no. 16716) was sub-cloned into the vector, pLX303 (Addgene plasmid no. 25897), using the Life Technologies Gateway system. pLenti6-hSIK2-WT and p-Lenti6-hSIK2-4A mutants were subcloned from pShuttle-CMV-GFP-SIK2-WT and pShuttle-CMV-GFP-SIK2-4xAAAA (S343/A; S358/A; T484/A; S587/A) (supplied by K. Sakamoto) into a modified pLenti6-Blast vector. All final plasmids were sequence verified. Murine Tp53 was knocked down using the miR-30-based LMS sh-p53.1224 retroviral vector 61 . All other knockdowns were performed using pLKO-based lentiviral shRNA vectors from The RNAi Consortium (TRC) library (Broad Institute), and were purchased from Molecular Profiling Laboratory, MGH. The CRISPR guides against Sik1, Sik2 and Sik3 were cloned into pLentiCRISPRV2 (Addgene no. 52961). Information on the shRNA and gRNA targeting sequences are shown in Supplementary Table 1 .
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Animal studies. Mice were housed in pathogen-free animal facilities. All experiments were conducted under protocol 2005N000148 approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital and comply with all regulations for the ethical conduct of research. Mice were maintained on a mixed 129SV/C57Bl/6 background. Data presented include both male and female mice. All mice included in the survival analysis were euthanized when criteria for disease burden were reached (including abdominal distension that impeded movement, loss of > 15% of body weight, laboured breathing and/ or abnormal posture). Mouse strains were obtained from Jackson Laboratories (Rosa26-LSL-rtTA, Jax stock no. 005572) and kindly provided by colleagues (Ptf1a-Cre 62 and Ptf1a-Cre ER (Jax stock no. 019378) mice from C. Wright, LSL-Kras G12D (Jax stock no. 008179) mice from D. Tuveson and T. Jacks and Tp53 Lox/Lox (Jax stock no. 008462) mice from A. Berns). To generate the doxycycline-inducible TetO-Gnas R201C mouse strain (Fig. 1a) , the Gnas R201C mutation was introduced into the mouse Gnas cDNA (Harvard PlasmID, Clone: MmCD00314350, NCBI RefSeq accession number BC038067 or NM_201616.2) using the Quickchange kit (Agilent Lexington, MA, no. 200521) according to the manufacturer's instructions. The Gnas R201C cDNA was then cloned into the pBS31 Prime transgenic targeting vector (Thermo Scientific Open Biosystems, no. MES4487). The targeting vector was co-electroporated into C2 mouse embryonic stem cells (Thermo Scientific Open Biosystems, no. MES4305) with a plasmid expressing FLPE recombinase (pCAGGS-FlpE, Thermo Scientific Open Biosystems, no. MES4488) as described 63 . This system involves single copy integration of the transgene downstream of the collagen-1 locus and under control of a doxycyclineinducible promoter. This system enables broad expression in different tissues depending on the expression pattern of the doxycycline-inducible rtTA transgene. Embryonic stem (ES) cells were screened for integration of the transgene by PCR and correctly targeted ES cells were injected into C57Bl/6 blastocysts. Chimaeras were crossed to the Ptf1a-Cre strain, and offspring were successively crossed with Rosa26-LSL-rtTA, and LSL-Kras G12D mice. Compound mutant animals were provided with doxycycline (200 μ g ml −1 ) in the drinking water beginning at 4 weeks of age and replaced weekly. A group of control KC and KGC mice that was not provided Dox was euthanized at 12 weeks. Rosa26-LSL-rtTA allele was present in each cohort. Histological examination of the pancreas of these mice revealed a comparable phenotype of focal low-grade PanIN (similar to KC mice receiving Dox supplementation; for example, see Fig. 1d,e ), confirming that the cooperative phenotypes observed in the KGC mice were due to inducible expression of Gnas R201C .
Ptf1a-Cre ER , LSL-Kras G12D , Tp53 Lox/Lox , and Rosa26-LSL-rtTA and TetO-Gnas R201C strains were intercrossed to obtain KGPC ER , KGC ER , KPC ER animals and controls. To activate Cre, 3-week old animals were injected intraperitoneally every other day with 100 mg kg −1 (body weight) tamoxifen dissolved in corn oil (total 4 doses). Doxycycline (200 μ g ml −1 ) was provided in the drinking water beginning at 4 weeks of age. To study the role of Gnas R201C in tumour maintenance, KGC mice were provided Dox supplemented water continually from age 4 weeks (Dox-On) or switched to Dox-free water after tumour detection by palpation at age 8-10 weeks (Dox-Off). The samples were collected at the indicated time points for histological analysis. For abdominal cyst fluid measurement, mice were euthanized at the indicated time points and abdominal cyst fluid was isolated and measured using a 30 ml syringe and 25 g needle.
For subcutaneous tumour studies, 2 × 10 5 KGC cells or KGPC ER cells (or modified versions of the same) were injected subcutaneously into the lower flank of NOD.CB17-Prkdc scid /J mice (6-10 weeks of age) (Jax stock no. 001303). Tumour size was assessed at indicated time points by caliper measurements of length and width and the volume was calculated according to the formula (length × width 2 )/2. For orthotopic transplantation studies 2 × 10 5 tumour cells were prepared in 50% matrigel and injected in a total volume of 30 μ l into the tail of the mouse pancreas as described. At the indicated time points the pancreas was harvested and processed for histology and IHC as described in the relevant sections. In experiments involving Dox treatment, Dox supplemented drinking water (200 μ g ml −1 ) was first provided one day before injection of the tumour cells. For human pancreatic cancer xenograft studies, 7.5-10 × 10 5 cells (in 50% matrigel) were subcutaneously injected into the lower flanks of the NOD.CB17-Prkdc scid /J mice (6-10 weeks of age). Tumour growth was followed by caliper measurement until the animals reached humane endpoint criteria.
Histology and immunohistochemical analysis. Tissue samples were fixed overnight in 4% buffered formaldehyde, embedded in paraffin, and then sectioned and stained with haematoxylin and eosin by the MGH Pathology Core. Histological examination was performed by a gastrointestinal cancer pathologist (M.M-K). Immunohistochemistry (IHC) was performed on paraffin-embedded sections (5 μ m thickness). After deparaffinization and dehydration, slides were incubated for 10 min with 3 % H 2 O 2 at room temperature to block endogenous peroxidase activity. Specimens were brought to the boil in 10 mM sodium citrate buffer (pH 6.0, 5 min, pressure cooker) for antigen retrieval. Slides were blocked for 1 hour in TBS-0.05 % Tween 20 (Fisher Scientific), 1 drop per 1 ml of Protein Block (Dako X0909) and incubated with primary antibody for 1 hour at room temperature. Primary antibodies were diluted with PBS-Protein Block (1 drop/ml) as follows; anti-MUC1 1:100, anti-MUC2 1:50, anti-MUC5AC 1:100, anti-CK19 1:50, anti-CDX2 1:500, anti-PCNA 1:5000, anti-phospho-(Ser/Thr) PKA substrate 1:200. Specimens were reacted for 30 min with the MACH2 HRP-Polymer reagent combined with secondary antibodies. Slides were then washed with PBS and stained for peroxidase for 1-2 min with the Betazoid DAB Chromogen reagent, washed with water and counterstained with haematoxylin, and mounted from xylene. For Alcian Blue staining, after deparaffinization and dehydration, specimens were rinsed with 3 % acetic acid and then incubated for 20 min with 1% Alcian Blue in 3% acetic acid. Stained slides were photographed with an Olympus DP72 microscope. For quantification of PCNA and phospho-PKA substrate by IHC, % of positively stained IPMN epithelial cell nuclei was counted automatically using ImageJ software (NIH; http://rsb.info.nih.gov/ij). Quantification of mucinproducing IPMN epithelial cells was performed by manually counting % IPMN epithelial cells with Alcian Blue-positive cytoplasm. For quantification of papillary lesions, the % of the total neoplastic ductal area exhibiting papillary structures was assessed using haematoxylin and eosin stained slides.
Isolation and culture of primary tumour cells. Murine pancreatic tumour cells were derived from the following GEM models: KGC (Kras G12D/+ ; Rosa26-LSL-rtTA Lox/+ , TetO-Gnas R201C , Ptf1a-Cre); KGPC (Ptf1a-Cre ER Kras G12D/+ ; Rosa26-LSL-rtTA Lox/+ , TetO-Gnas R201C ; p53 Lox/+ ); KPC (Pdx1-Cre; Kras G12D/+ ; p53 Lox/+ ); KIC (Pdx1-Cre; Kras G12D/+ ; Ink4a/Arf Lox/+ ); KPIC (Pdx1-Cre; Kras G12D/+ ; p53 Lox/+ ;p16 +/− ). Tumour tissues were collected in ice cold 20 ml DMEM with 1 × Antibiotic-Antimycotic. A transection of the tumour tissue was taken for histological verification and the rest was washed twice with 10 ml HBSS and then minced aseptically with a razor blade on a 10-cm dish. The minced tissue was digested in a small flask for 1 hour on a bench-top stirrer with 2.6 U Liberase DH in 10 ml DMEM containing 1 × Antibiotic-Antimycotic at 37 °C. 10 mL tissue homogenates were transferred to a 50 ml falcon tube and centrifuged at 1,000 rpm, 5 min, 4 °C. The pellet was then washed with HBSS 2-3 times by centrifugation. A 100 μ m strainer was used to removed undigested large tissue debris. The flow-through was centrifuged at (RCF 335) × g for 5 minutes, and the pellet was resuspended with full duct media (DMEM:F12, 5 mg/ml Glucose, 1.22 mg ml −1 nicotinamide, 5 nM 3,3,5-tri-iodo-L-thyronine, 1 μ M dexamethasone, 5 ml l −1 ITS+ , 1 × Pen/Strep, 20 ng ml −1 mouse EGF, 5% NuSerum IV and 25 μ g ml −1 bovine pituitary extract) with Rho-associated protein kinase (ROCK) inhibitor (10 μ g ml −1 )) and plated on irradiated feeder cells. Media was supplemented with 200 ng ml −1 doxycycline. The frozen cells were thawed on feeder layer with ROCK inhibitor and grown as organoids in matrigel or collagen matrix as described unless otherwise stated. For viral infections primary cells were plated in feeder or laminin-coated multi-well plates and infected by spinoculation. KGC shp53 cells were initially generated by infecting KGC cells with the LMS sh-p53 retrovirus. PDA cell lines derived from 1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The proteomics data have been deposited in MassIVE proteomics data depository (https://massive.ucsd.edu/) with accession number MSV000082305. The RNA-seq data have been deposited in the NCBI GEO database with accession number GSE114348. The lipidomic and polar metabolite data can be accessed under 10.6084/
